Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists

Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists

US Patent 9982029 · Granted May 29, 2018

Estimated economic value: $11,844,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Polymer nanoparticle compositions for in vivo expression of polypeptides2025
FGFR1/KLB targeting agonistic antigen-binding proteins and conjugates thereof wi2024
Method for cleavage of solid phase-bound peptides from the solid phase2023
GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and ste2022
GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and ste2022
GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and ste2022
Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic ac2021
Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic ac2021
Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic ac2021
Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic ac2021
Selective glucagon receptor agonists comprising a chelating moiety for imaging p2021
Selective glucagon receptor agonists comprising a chelating moiety for imaging p2021